Skip to content
OpenCapital
Get started

Trevi Therapeutics, Inc. TRVI Q2 2025 earnings

Reported August 7, 2025 · After market close

EPS-$0.09Beat by $0.01
EPS estimate-$0.10

Next report

Aug 6, 2026 (In 1 week)
EPS estimate-$0.11

Financials

Q2 2025

Income statement

See full
Operating income-$13.7M-3.3%
Net income-$12.3M+0.4%
EPS (diluted)-$0.09+25.0%

Balance sheet

See full
Cash & equivalents$117.1M+803%
Total debt$891.0K-30.7%
Total equity$198.5M+200%
Total assets$208.3M+182%

Cash flow

See full
Operating cash flow-$10.1M-16.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$702.53M+137%
Enterprise value$586.36M+106%

Returns & leverage

See full
Return on equity-35.7%-7.3pp
Debt / equity0×0.0×
Current ratio22.4×+11.7×

Versus estimates

Diluted EPS

Q1 2026-$0.09Miss by $0.02Q4 2025-$0.06Beat by $0.04Q3 2025-$0.08Beat by $0.02
Q2 2025-$0.09Beat by $0.01
Q1 2025-$0.09Beat by $0.04Q4 2024-$0.11Beat by $0.01

Ask the moment Trevi Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Trevi Therapeutics, Inc. report Q2 2025 earnings?
Trevi Therapeutics, Inc. (TRVI) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Trevi Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Trevi Therapeutics, Inc. reported eps of $-0.09 for Q2 2025.
Did Trevi Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.10 by $0.01.
How did Trevi Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 25.0% from $-0.12.
Where can I find Trevi Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-105066) directly on SEC EDGAR. The filing index links above go to sec.gov.